Enlivex Therapeutics (ENLV) Expected to Announce Earnings on Friday

Enlivex Therapeutics (NASDAQ:ENLV) is expected to be releasing its Q1 2025 results before the market opens on Friday, August 29th. Analysts expect Enlivex Therapeutics to post earnings of ($0.16) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q1 2025 earningoverview page for the latest details on the call scheduled for Thursday, August 28, 2025 at 6:00 PM ET.

Enlivex Therapeutics (NASDAQ:ENLV) last issued its quarterly earnings data on Friday, May 30th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01. On average, analysts expect Enlivex Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Enlivex Therapeutics Trading Down 6.4%

ENLV opened at $1.03 on Friday. The firm has a market cap of $24.36 million, a P/E ratio of -1.56 and a beta of 0.80. Enlivex Therapeutics has a 12 month low of $0.8101 and a 12 month high of $2.10. The stock has a 50-day moving average of $1.26 and a 200 day moving average of $1.10.

Analyst Ratings Changes

Separately, D. Boral Capital reiterated a “buy” rating and issued a $13.00 price target on shares of Enlivex Therapeutics in a research report on Monday. One analyst has rated the stock with a Strong Buy rating and two have assigned a Buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $10.00.

Institutional Trading of Enlivex Therapeutics

An institutional investor recently raised its position in Enlivex Therapeutics stock. Jane Street Group LLC boosted its position in Enlivex Therapeutics Ltd. (NASDAQ:ENLV) by 527.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 80,759 shares of the company’s stock after purchasing an additional 67,886 shares during the period. Jane Street Group LLC owned approximately 0.34% of Enlivex Therapeutics worth $78,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 1.02% of the company’s stock.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.